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Abstract
Growing evidence suggests a mechanistic link between inflammation and the
development and progression of fibrotic processes. Mesenchymal stromal cells
derived from the human amniotic membrane (hAMSCs), which display marked
immunomodulatory properties, have been shown to reduce bleomycin-induced
lung fibrosis in mice, possibly by creating a microenvironment able to limit the
evolution of chronic inflammation to fibrosis. However, the ability of hAMSCs to
modulate immune cells involved in bleomycin-induced pulmonary inflammation
has yet to be elucidated. Herein, we conducted a longitudinal study of the effects
of hAMSCs on alveolar and lung immune cell populations upon bleomycin chal-
lenge. Immune cells collected through bronchoalveolar lavage were examined by
flow cytometry, and lung tissues were used to study gene expression of markers
associated with different immune cell types. We observed that hAMSCs increased
lung expression of T regulatory cell marker Foxp3, increased macrophage polariza-
tion toward an anti-inflammatory phenotype (M2), and reduced the antigen-
presentation potential of macrophages and dendritic cells. For the first time, we
demonstrate that hAMSCs markedly reduce pulmonary B-cell recruitment,
retention, and maturation, and counteract the formation and expansion of
intrapulmonary lymphoid aggregates. Thus, hAMSCs may hamper the self-
maintaining inflammatory condition promoted by B cells that continuously act as
antigen presenting cells for proximal T lymphocytes in injured lungs. By modulat-
ing B-cell response, hAMSCs may contribute to blunting of the chronicization of
lung inflammatory processes with a consequent reduction of the progression of
the fibrotic lesion.
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1 | INTRODUCTION
The pathogenesis of idiopathic pulmonary fibrosis (IPF) is still
poorly understood, thus heavily contributing to the lack of an
effective cure.
There is growing evidence suggesting a mechanistic link between
inflammation, which endures to the end stage of IPF, and the develop-
ment and progression of fibrosis.1-4
Interestingly, we and others have reported that cells derived from
the amniotic membrane of human term placenta, such as amniotic epi-
thelial cells and amniotic mesenchymal stromal cells (hAMSCs)5-10 and
related secretome,11-13 can prevent and reduce the progression of
pulmonary fibrosis when injected in bleomycin-instilled rodents, a
model which closely resembles human IPF.14
Amniotic cells and their secreted factors possess in vitro and in vivo
immune-modulatory properties. They inhibit T-cell proliferation,15-18
reduce the production of proinflammatory cytokines,6,7,18,19 block the
differentiation/maturation of monocytes into dendritic cells,20-22 pro-
mote macrophage polarization toward an M2 anti-inflammatory
phenotype,8,23,24 induce regulatory T cells,18,25,26 and reduce natural
killer cytotoxicity.27
However, to the best of our knowledge, no studies investigated
the crosstalk between hAMSCs and immune cell populations that are
involved in bleomycin-induced lung injury.
Herein, we sought to explore whether hAMSC treatment affects
the levels and phenotype of immune cell populations in alveolar
spaces and in lung tissue during the course of bleomycin-induced lung
injury, and its potential correlation to therapeutic outcome.
Furthermore, in an attempt to address the important question
about the impact of in vitro culture on hAMSC therapeutic effects, in
this study we used both nonexpanded passage 0 hAMSCs (hAMSC/
P0) and hAMSCs expanded in vitro to passage 2 (hAMSC/P2).
2 | MATERIALS AND METHODS
2.1 | Ethics statement
Human term placentae were collected from healthy subjects,
according to the guidelines of the Ethical Committee of the Province
of Brescia (Comitato Etico Provinciale, approval CEP 19.01.2016).
Animal experiments were carried out in accordance with the
guidelines established by the Italian law DL 26/2014. The experimen-
tal protocol was approved by Italian Ministry of Health (Authorization
n. 779/2016-PR) and by the Committee on the Ethics of Animal
Experiments of the University of Milano (n. 105/14, 9/12/2014).
2.2 | hAMSCs isolation, culture, and
characterization
Twelve amniotic membranes were collected and processed as previ-
ously described.28 Briefly, the amniotic membrane was manually
separated from the chorion, rinsed in saline solution containing
100 U/mL penicillin and 100 μg/mL streptomycin (both from Sigma-
Aldrich, St. Louis, Missouri), fragmented (~3 × 3 cm2) and then
digested at 37C with 2.5 U/mL dispase (Corning, New York). After
9 minutes, the amnion was washed in RPMI 1640 medium (Sigma-
Aldrich) supplemented with 10% fetal bovine serum (FBS; Sigma),
2 mM L-glutamine (Sigma-Aldrich), and P/S (herein referred to as
complete RPMI medium), and finally digested for 2.5 hours with
0.94 mg/mL collagenase and 0.01 mg/mL DNase (both from Roche,
Basel, Switzerland). Isolated cells were filtered (100 μm strainer, BD
Falcon, Bedford, Massachusetts), collected by centrifugation,
resuspended in complete RPMI medium, and refiltered (70 μm strainer
BD Falcon). All cell batches were used as individual preparations that
were cryopreserved and/or in vitro cultured.
Freshly isolated cells (hAMSC/P0) were frozen in 90% FBS and
10% dimethyl sulfoxide (DMSO; Sigma-Aldrich) and stored in liquid
nitrogen until further use. Alternatively, isolated cells (hAMSC/P0)
were plated at a density of 10 000 cells/cm2 in CHANG Medium-C
(Irvine Scientific, Santa Ana, California) supplemented with 2 mM
L-glutamine and P/S. When reaching 80% confluence, cells were sub-
cultured at a density of 10 000 cells/cm2. Expanded hAMSCs (passage
2; hAMSC/P2), were detached and frozen as described above.
Both hAMSC/P0 and hAMSC/P2 were phenotypically character-
ized for the expression of mesenchymal (CD105, CD90, CD73,
CD13), hematopoietic (CD45) and epithelial (CD326) markers by flow
cytometry (FACS Calibur cytometer), as previously reported.21 The
following antibodies were used: anti-CD90 (1:500, clone 5E10); anti-
CD73 (1:50, clone AD2), anti-CD13 (1:500, clone L138), anti-CD45
(1:250, clone 2D1), and anti-CD326 (1:50, clone EBA-1) all from BD
Biosciences (San Jose, California); and anti CD105 (1:50, clone SN6
from Serotec, Oxford, UK).
Cells whose viability after thawing was higher than 85% were
used. Nonexpanded and in vitro expanded cell preparations were used
in order to study the possible impact of in vitro culture on hAMSC
therapeutic effects.
Significance statement
The immunomodulatory features of amniotic cells can create
a microenvironment able to limit the evolution of chronic
inflammation to fibrosis. However, the immune modulation
induced by amniotic mesenchymal stromal cells (hAMSCs) in
models of fibrosis has yet to be elucidated. For the first
time, this study shows that in bleomycin-challenged mice,
hAMSCs control pulmonary B-cell recruitment, retention,
maturation, and reduce the formation and expansion of lung
lymphoid aggregates. By modulating B-cell response,
hAMSCs hamper the self-maintaining inflammatory condi-
tion promoted by B cells in injured lungs and may contribute
to limiting the chronicization of lung inflammation that evo-
lves into the fibrotic lesion.
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2.3 | Induction of lung injury and treatment
All experimental procedures were performed on animals anesthetized via
intramuscular injection with Tiletamine chloride + zolazepam chloride
(Zoletil-100, Virbac, Milano, Italy, at 0.3 mL/30 mg/kg) and xylazine
(Ronpum, Bayer Schering PharmaAG, Leverkusen, Germany, at 2 mg/kg).
Lung injury was induced by intratracheal (i.t.) instillation of
bleomycin (40 μL; 2.3 U/kg; Bleoprim, Sanofi-Aventis, Milano) in 8- to
9-week-old female C57BL/6 mice (Charles River, Calco, Italy).5
Healthy control animals received 40 μL of saline.
Fifteen minutes after treatment with bleomycin or saline, 1 × 106
hAMSC/P0 or hAMSC/P2 were injected i.t., as previously described.5
Control animals were injected with only 150 μL sterile PBS.
Each treatment group (Bleo+PBS, Bleo+hAMSC/P0, and Bleo
+hAMSC/P2) consisted of n = 26 animals. Notably, each treatment group
was composed of five different time point subgroups: day 2 (n = 3); day
4 (n = 4); day 7 (n = 5); day 9 (n = 7), and day 14 (n = 7). The size of each
treatment/time point group is indicated in each figure.
2.4 | Sample collection
Each animal was anesthetized as described above and euthanized at the
scheduled time point by exsanguination. Blood was drained from the
abdominal aorta and bronchoalveolar lavage (BAL) was collected using a
total volume of 2.0 mL of sterile PBS injected i.t. with a 20-gauge can-
nula. BAL fluids were centrifuged (1000g for 10 minutes, at 4C) and
cells were frozen in 90% FBS+10% DMSO for flow cytometry analysis.
Lungs were explanted and sectioned into the five individual lobes
as previously described.12 Each lobe was further sectioned into two
equivalent hemilobes. One series of hemilobes was formalin-fixed
(10% neutral formalin from Bio-Optica, Milano, Italy) for 48 hours at
room temperature and processed for microscopic analyses. The other
series of pooled hemilobes was snap-frozen in liquid nitrogen and
stored at −80C for real-time polymerase chain reaction (RT-PCR)
analysis.
2.5 | Microscopy and image analysis
Lung hemilobes were paraffin-embedded and consecutive 4-μm-thick
sections were cut. Sequential, nonoverlapping images were captured
from whole hematoxylin and eosin or Masson's trichrome-stained sec-
tions with a digital camera (Olympus Camedia C-4040 ZOOM) in
bright-field light microscopy (Olympus BX41, Tokyo, Japan) at 40×
magnification. Color digital images obtained from each hemilobe were
converted by the FiJi software (https://imagej.nih.gov/ij) to binary
data, and the percentage of each alveolar hemilobe pixels to whole
hemilobe pixels was calculated. The area occupied by alveoli of the
entire lung was the sum of all hemilobe alveolar areas and was
expressed as a percentage of total area of the entire lung section.9,29
All analyses were performed in a blinded manner by a veterinary
pathologist.
2.6 | Flow cytometry analysis
BAL cells were stained with Zombie NIR Live/Dead Cell Kit
(eBiosciences, San Diego, California) for live/dead discrimination
according the manufacturer's instructions. After 5 minutes incubation
with CD16/CD32 (Mouse Fc Block, BD Biosciences), cells were sta-
ined for 20 minutes at 4C with the following anti-mouse antibodies:
CD45 FITC (1:1000, 553080 clone 30-F11), CD3e PE (1:160, 553063
clone 145-2C11); CD4 BV421 (1:2000, 740007 clone RM4-5), CD8a
BV510 (1:160, 563068 clone 53-6.7), CD25 PE-CF594 (1:100,
562694 clone PC61), B220 PerCP-Cy5.5 (1:500, 561101 clone
RA3-6B2), CD19 PE-Cy7 (1:100, 552854 clone 1D3), CD11b BV421
(1:200, 562605 clone M1/70), CD11c PE-Cy7 (1:100, 558079 clone
HL3), I-A/I-E (MHC-II) BV510 (1:330, 742893 clone M5/114.15.2),
CD24 APC (1:2000, 562349 clone M1/69), CD64 PE (1:500, 558455
clone X54-5/7.1), Siglec-F PE-CF594 (1:200, 562757 clone
E50-2440), and CD80 BV510 (1:100, 740130 clone 16-10A1; all from
BD Biosciences).
In order to detect intracellular expression of FoxP3, cells were fixed
and permeabilized with Cytofix/cytoperm solution (BD Biosciences;
20 minutes, 4C) and subsequently incubated with anti-mouse FoxP3
A647 (1:200, 563486 clone R16-715; BD Biosciences) for 30 minutes
at 4C.
Antigen expression was detected using BD FACSAria III equipped
with the BDFACSDiva software (BD Biosciences) and data were ana-
lyzed with the FCSExpress 5.0 software (DeNovo Software, Los
Angeles, California).
Cell populations were identified by sequential gating strategy
following previously published protocols30-32 with modifications. Briefly,
cells were identified as follows: neutrophils (CD11b+ CD11c− CD24+
Siglec-F−); alveolar macrophages (CD64+ CD24− CD11c+ CD11b−
Siglec-F+); monocyte-derived alveolar macrophages (CD64+ CD24−
CD11c+ CD11b+ Siglec-Flow/−); dendritic cells CD11b− (CD64− CD24+
I-A/I-E+ Siglec-F− CD11b−); dendritic cells CD11b+ (CD64− CD24+ I-A/I-
E+ Siglec-F− CD11b+); B lymphocytes (CD3− B220+ CD19+); T lympho-
cytes (CD3+ CD4+ and CD3+ CD8+); regulatory T cells (CD3+ CD4+
CD25+ FoxP3+). The gating strategy applied for cell identification is
reported in Supporting Information Figure S1. All cells contained within
the BAL collected from each animal were analyzed. At least 20 000 events
for each BAL samplewere acquired after surface or intracellular staining.
Results are presented as percentage of viable cells. The CD80
marker is expressed as median fluorescence intensity ratio between
positive and negative cells. Specific isotype controls were used.
2.7 | Quantitative RT-PCR
Gene expression in lung tissue of podoplanin, α-SMA, fibronectin, and
collagen was determined by RT-PCR as follows. Total RNA was
extracted from snap-frozen lung hemilobes using EZ1 RNA Universal
Tissue Kit (Qiagen, Hilden, Germany) following manufacturer's instruc-
tions. cDNA was prepared with ImProm-IITM Reverse Transcription
System (Promega, Madison, Wisconsin). Quantitative RT-PCR was
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performed using PowerUp Green Master Mix SYBR Green PCR mas-
ter kit (Life Technologies) on a ABIPRISM 7000 instrument (Applied
Biosystems). Data were normalized to the housekeeping gene (β-actin)
and relative gene expression was quantified using the 2−ΔCT method.
Primer sequences are shown in Supporting Information Table S1.
2.8 | Immunofluorescence and quantification of
lymphoid aggregates
CD3+ T, B220+ B, and CD138+ antibody-secreting cells were identified by
immunofluorescence as follows. Paraffin-embedded sections of lung tis-
sue (4 μm) were de-waxed and rehydrated in water. Antigen retrieval was
performed with 10 mM citrate buffer, pH 8.0 (W-CAP from Bio-Optica,
Milano, Italy) at 98C for 10 minutes. After blocking (10% normal goat
serum, ThermoFisher Scientific, SanDiego, California), sectionswere incu-
bated with polyclonal rabbit anti-CD3 antibody (1:20, Dako, Glostrup,
Denmark) and rat anti-CD45R/B220 antibody (1:100, Clone RA3-6B2,
Thermo Fisher Scientific) or polyclonal rabbit anti-CD138 antibody (1:50,
Thermo Fisher Scientific) at 4C O/N. After washing, sections were incu-
bated with secondary Cy5 anti-rat antibody (5 μg/mL, Vector Laborato-
ries, Inc, Burlingame, California) or biotinylated anti-rabbit antibody (IgG(H
+L), Vector Laboratories), followed by DyLight 488 Streptavidin (2 μg/mL,
Vector Laboratories). Images were acquired using the Nikon Eclipse Ni-U
microscope equippedwithMonoCameraNikonDS-Fi3 Version 4.60.
Lymphoid aggregates were counted in two sections of all lung
hemilobes by CD3/B220 expression. The size of each aggregate was
measured using the FiJi software and the cumulative area occupied by
lymphoid aggregates was calculated as the sum of all individual areas
present in all lung hemilobes per section. Lymphoid aggregates were
stratified according to their size (small: 5000-10 000 μm2; intermedi-
ate: 10 000-20 000 μm2; large: >20 000 μm2), and proportion of B
cells with respect to the whole lymphoid population (low: 0%-10%;
intermediate: 10%-40%; large: 41%-70%).
F IGURE 1 Human amniotic mesenchymal stromal cells (hAMSCs) ameliorate bleomycin-induced lung injury. Compared to saline, bleomycin
instillation (black bars) produced a marked drop of podoplanin expression (a marker of type I alveolar epithelial cells), (A, Bleo+PBS group) and a
progressive reduction of lung alveolar area (B, Bleo+PBS group), due to interstitial septa thickening and alveolar obliteration (C, Bleo+PBS group).
Moreover, bleomycin challenge increased lung expression of α-SMA (a marker of myofibroblasts), (F, Bleo+PBS group), and of extracellular matrix
proteins such as fibronectin (G, Bleo+PBS group) and collagen (H, Bleo+PBS group). Treatment with hAMSCs (at passage 0 = hAMSC/P0, white
bars or at passage 2 = hAMSC/P2, gray bars) preserved lung gene expression of podoplanin (A) and alveolar area (B), and decreased alveolar
obliteration (D,E). Moreover, hAMSCs reduced lung gene expression of α-SMA (F), fibronectin (G), and collagen (H). Data from mRNA levels
analysis are expressed as log2 of the fold change from the saline-instilled group. These data are reported as mean ± SE of n = 3 (day 2); n = 4 (day
4) and n = 5-7 (days 7, 9, and 14) samples. Microphotographs are representative of lung tissues collected from Bleo+PBS group (C), Bleo
+hAMSC/P0 (D), and Bleo+hAMSC/P2 (E) at day 14 postbleomycin. Scale bars = 100 μm. *P < .05, **P < .01, ***P < .001 compared to control
(Bleo+PBS) group
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2.9 | Statistical analysis
All data are presented as mean ± SE of three independent experiments.
Differences between groups were analyzed by one-way analysis of vari-
ance, followed by Tukey's multiple comparisons test. A P-value <.05 was
considered statistically significant. Statistical analyses were performed
using the Prism6.05 software (Graphpad software Inc., La Jolla, California).
3 | RESULTS
3.1 | hAMSCs ameliorate bleomycin-induced lung
injury
To explore the potential benefits exerted by hAMSCs, we evaluated
bleomycin-induced lung injury by measuring residual alveolar area and
gene expression of markers indicative of alveolar integrity (eg,
podoplanin)33 and associated with progression of fibrotic lesions (eg,
α-SMA, fibronectin, and collagen).
Alveolar epithelial damage occurred early after bleomycin instilla-
tion (at day 2) as shown by marked decrease of lung podoplanin gene
expression by 84.2% ± 0.1% (Figure 1A).
At day 14 postinstillation, the alveolar area assessed in animals of
Bleo+PBS group declined (from 54.0 ± 2.5 to 35.1 ± 0.7 in saline and
bleomycin-instilled mice, respectively; P < .01; Figure 1B) as a result of a
progressive interstitial septa thickening and alveolar obliteration
(Figure 1C).
Treatment with hAMSCs preserved lung expression of podoplanin
at days 2 and 4 (Figure 1A), as well as better maintained residual alveolar
area (Figure 1B) with decreased alveolar obliteration (Figure 1D,E).
In addition, hAMSCs induced a significant reduction of lung gene
expression of α-SMA (a myofibroblast marker) at days 4 and
F IGURE 2 Human amniotic mesenchymal stromal cells (hAMSCs) alter antigen presenting cells in bleomycin-induced inflammation. Bleomycin
challenge increased alveolar levels of both monocyte-derived alveolar macrophages (Mo-Av Macrophages, Mo-AM) (A, Bleo+PBS group) and CD11b+
dendritic cells (DC) (B, Bleo+PBS group). hAMSC treatment did not affect levels of Mo-AM and DC (A,B), however it reduced the levels of Mo-AM and
DC expressing the costimulatory molecule CD80 (C,D) and more strongly reduced the density with which CD80 was expressed on the surface of these
cells (E,F). With regard to macrophage subsets, bleomycin challenge increased lung mRNA expression of F4/80 (a pan marker of macrophages; G, Bleo
+PBS group) and of iNOS (a marker of M1 macrophages; H, Bleo+PBS group) while did not change expression of Ym-1 (a marker of M2 macrophages,
I). hAMSC treatment did not affect expressions of F4/80 and iNOS, in contrast it increased the expression of Ym-1 (I), suggesting a polarization toward
M2 anti-inflammatory phenotype. Alveolar levels of Mo-AM and DC were analyzed by flow cytometry, as percentage of viable CD45 positive cells in
bronchoalveolar lavage collected from bleomycin-challenged mice treated with amniotic cells (Bleo+hAMSC/P0 and Bleo+hAMSC/P2) or not (Bleo
+PBS). Density of CD80 expression was evaluated as median fluorescence intensity ratio between positive and negative cells. Data from mRNA levels
analysis are expressed as log2 of the fold change from the saline-instilled group. These data are reported as mean ± SE of n = 4 (day 4) and n = 5-7
(days 7, 9, and 14) samples. *P < .05, **P < .01 compared to control (Bleo+PBS) group
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9 (Figure 1F), and a decrease in expression of extracellular matrix pro-
teins such as fibronectin (Figure 1G) and collagen (Figure 1H) occurred
at all time points.
3.2 | hAMSCs alter antigen presenting cells in
bleomycin-induced inflammation
To investigate a possible link between the immune-modulatory prop-
erties of hAMSCs and their ability to limit the progression of lung
fibrosis, we studied the capacity of hAMSCs to reduce bleomycin-
induced recruitment of inflammatory cells into alveolar spaces and
lung tissue, as well as their polarization and maturation.
Bleomycin challenge induced a recruitment of inflammatory cells
into alveolar spaces. hAMSC treatment did not affect the alveolar
recruitment of CD45+ cells at any time point (see Supporting Informa-
tion Table S2); however, relative differences among CD45+ cell sub-
populations were observed.
Bleomycin instillation produced marked alterations of immune
populations present in alveolar spaces. In bleomycin-instilled animals,
F IGURE 3 Human amniotic mesenchymal stromal cells (hAMSCs) alter T lymphocyte subsets in bleomycin-induced inflammation. Bleomycin
instillation produced recruitment of T lymphocytes in alveolar spaces (A, Bleo+PBS group), and increased both CD4+ and CD8+ T-cell
subpopulations (B,C, Bleo+PBS group). hAMSC treatment slightly and transiently increased T lymphocyte recruitment (A-C). Panels D-F report
lung mRNA levels of markers associated with distinct subsets of T lymphocytes including Tbet (related to Th1 cells), GATA3 (Th2), and ROR-γτ
(Th17). Bleomycin challenge increased the expression of these markers (D-F, Bleo+PBS group). hAMSC treatment transiently increased
expression of Tbet (D, day 4) and of GATA3 (E, day 7), while reducing ROR-γτ gene expression (F, day 4). Panels G-I report gene lung expressions
of cytokines secreted by Th1 T-cell subset (IL-1β and IFN-γ, G,H) and Th2 subset (IL-4, I). Bleomycin challenge increased expressions of IL-1β and
IFN-γ (G,H, Bleo-PBS group), except IL-4 which is reduced compared to saline instillation (I, Bleo+PBS group). Treatment with hAMSCs did not
change lung expression of IFN-γ (G), reduced that of IL-1β (H), and increased that of IL-4 (I), suggesting a polarization toward Th2 T-cell subset.
Panels J-L show alveolar levels of T regulatory (Treg) cells and the expression of markers related to an anti-inflammatory milieu. Compared to
saline-instilled group, animals challenged with bleomycin displayed increased levels of alveolar Treg (J, Bleo+PBS group), accompanied by
increased gene expression of lung Foxp3 (K, Bleo+PBS group) and IL-10 (L, Bleo+PBS group). This effect was further strengthened by treatment
with hAMSCs, that increased lung expression of Foxp3 (K, days 4 and 7) and of IL-10 (L, days 7 and 9). Alveolar levels of T lymphocytes were
analyzed by flow cytometry and expressed as percentage of viable CD45 positive cells in bronchoalveolar lavage collected from each mouse. Data
from mRNA levels analysis are expressed as log2 of the fold change from the saline-instilled group. These data are reported as mean ± SE of n = 4
(day 4) and n = 5-7 (days 7, 9, and 14) samples. *P < .05, **P < .01 compared to control (Bleo+PBS) group
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we observed a marked decline of relative amount of resident alveolar
macrophages, identified as CD64+ CD11c+ Siglec-F+ cells, which rep-
resent the predominant cell population in normal conditions. Their
percentage fell from 78.2% ± 2.4% in the saline control group, to
41.8% ± 5.8% and 8.6% ± 2.9% after 4 and 7 days from bleomycin
instillation, respectively. In contrast, the percentage of not resident
monocyte-derived macrophages (identified as CD64+ CD11c+ Siglec-
Flow/− cells and herein referred to as Mo-Alv macrophages) increased
from 0.8% ± 0.3% in saline-instilled mice to 10.9% ± 3.4% at day
4 postbleomycin and maintained stable up to day 14 (Figure 2A). It is
of note that a large percentage of Mo-Alv macrophages (78.5%
± 13.1%) expressed the costimulatory molecule CD80, in contrast
with the low percentage (12.8% ± 5.8%) of CD80-expressing resident
alveolar macrophages. Given the crucial role played by CD80 in trig-
gering T-cell mediated antigen-specific inflammatory responses, this
finding suggests that bleomycin promotes the recruitment of Mo-Alv
macrophages which can act as antigen presenting cells more effi-
ciently than resident alveolar macrophages.
Similar to Mo-Alv macrophages, alveolar percentage of dendritic
cells, another immune population with crucial antigen presenting
activity, increased from 0.12% ± 0.06% in saline-instilled mice to
2.45% ± 0.31% at day 7 postbleomycin (Figure 2B). Dendritic cells
have been identified as CD11b+ MHCII+ CD11c+ CD24− CD64− cells,
and herein referred to as CD11b+ DCs (Figure 2B).
Notably, hAMSC treatment did not affect neither the levels of
resident (data not shown) and Mo-Alv macrophages (Figure 3A), nor
that of CD11b+ DCs (Figure 2B). Instead, it reduced the percentage of
Mo-Alv macrophages (Figure 2C) and of CD11b+ DCs (Figure 2D)
expressing the costimulatory molecule CD80 and decreased also the
density of CD80 expression on their membranes (Figure 2E,F).
With regard to distinct macrophage subsets, we found that
bleomycin challenge increased lung gene expression of the pan
F IGURE 4 Human amniotic mesenchymal stromal cells (hAMSCs) reduce bleomycin-induced recruitment and maturation of B cells.
Bleomycin instillation produced a progressive recruitment of B cells in alveolar spaces (A, Bleo+PBS group) and increased mRNA expression of
B220 (a marker specifically expressed by B lymphocytes) in lung tissue (B, Bleo+PBS group). hAMSC treatment markedly decreased B-cell levels
in alveolar spaces (A) and lung expression of B-cell marker B220 (B). hAMSC treatment also decreased the number of CD138 positive cells
(antibody-secreting B cells) in lung tissues (C), suggesting that treatment control the maturation of B cells. Alveolar levels of B cells were analyzed
by flow cytometry as percentage of CD3 negative cells in bronchoalveolar lavage collected from bleomycin-challenged mice treated with amniotic
cells (Bleo+hAMSC/P0 and Bleo+hAMSC/P2) or not (Bleo+PBS). Data from mRNA levels analysis (B) are expressed as log2 of the fold change
from the saline-instilled group. These data are reported as mean ± SE of n = 4 (day 4) and n = 5-7 (days 7, 9, and 14) samples. CD138 positive
cells were counted in whole lung sections derived from mice of all treatment groups, at 14 days from bleomycin challenge. *P < .05, **P < .01
compared to control (Bleo+PBS) group
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macrophagic marker F4/80 and of the markers associated with macro-
phage polarization toward M1 (iNOS) and M2 (Ym-1) phenotype. As
shown in Figure 2, hAMSC treatment did not alter the expression of
F4/80 (Figure 2G) or of iNOS (Figure 2H) in lung tissue, whereas it
induced the expression of Ym-1 at days 4 and 7 (Figure 2I).
Altogether, these data suggest that hAMSC treatment pro-
motes a shift toward immune phenotypes with lower inflammatory
potential by decreasing CD80 expression and density on macro-
phages and dendritic cells, and by increasing expression of macro-
phage M2 markers.
3.3 | hAMSCs alter T lymphocyte subsets in
bleomycin-induced inflammation
We also studied the ability of hAMSCs to counteract bleomycin-
induced alterations in alveolar and lung T-cell environment.
Alveolar CD3+ T lymphocytes, which represent only 1.9% ± 0.9%
of the total CD45+ population in saline-instilled mice; increased to
13.9% ± 3.0% (day 4) and to 47.9% ± 8.1% (day 14) in bleomycin-
instilled animals (Figure 3A), with higher percentage of CD4+ cells
compared to CD8+ cells (Figure 3B,C). hAMSC treatment did not
reduce T lymphocyte recruitment, rather at day 4 it slightly increased
the early recruitment of CD3+ cells, including both CD4+ and CD8+
subpopulations (Figure 3A-C).
To reveal whether hAMSC treatment differently affects dis-
tinct inflammatory subsets of CD4+ T cells, we determined the lung
gene expression of markers associated to Th1 (Tbet), Th2 (GATA3),
and Th17 (ROR-γτ) T-cell subsets and of cytokines with
proinflammatory action (IFN-γ, IL-1β, and IL-4). As shown in
Figure 3, bleomycin transiently increased Tbet and ROR-γτ lung
expression while GATA3 expression was high at all time points,
suggesting an early role of Th1 and Th17 cells in contrast to a more
consistent presence of Th2 cells in bleomycin-challenged lungs
F IGURE 5 Human amniotic mesenchymal stromal cells (hAMSCs) reduce the presence of lymphoid aggregates in lung tissues of
bleomycin-challenged mice. Lymphoid aggregates (indicated with black arrows) were present in the lungs of bleomycin-challenged mice.
They were located in peri-bronchial areas as shown in lung sections stained with hematoxylin and eosin (A,B). Immunofluorescence double
staining for CD3 (T cells, green) and B220 (B cells, red) indicated that lung lymphoid aggregates are composed of T and B lymphocytes mixed
in variable proportions (C-F). Here, examples of aggregates with low (C,D), intermediate (E), and large (F) presence of B cells are reported.
Scale bars = 100 μm (A,B); 50 μm (C-F)
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(Figure 3D-F). In line with the increased recruitment of CD3+ cells
in alveolar spaces, we found that hAMSCs transiently induced Th1
and Th2 responses as indicated by the increased expression of Tbet
at day 4 (Figure 3D) and of GATA-3 at day 7 (Figure 3E). Instead,
they transiently reduced Th17 response, as indicated by declined
expression of ROR-γτ at day 4 (Figure 3F). Moreover, the treatment
with hAMSCs decreased the expression of IL-1β (Figure 3G) while
increased the expression of IL-4 (Figure 3H). The treatment did not
affect IFN-γ expression (Figure 3I).
We also investigated the ability of hAMSCs to promote an
immune suppressive milieu, by detecting the levels of alveolar T regu-
latory (Treg) cells, lung expression of the Treg marker Foxp3 and of IL-
10, a cytokine with important anti-inflammatory activity. hAMSC
treatment did not consistently affect alveolar Treg cell levels
(Figure 3J), however it augmented expression of Foxp3 at days 4 and
7 (Figure 3K) and of IL-10 at days 7 and 9 (Figure 3L) in lungs.
It is of note that hAMSC treatment did not affect neutrophil alve-
olar recruitment, whose relative levels transiently peaked at day
4 after bleomycin instillation (data not shown).
3.4 | hAMSCs reduce bleomycin-induced
recruitment and maturation of B cells
To refine the picture of the inflammatory environment in our mouse
model of fibrosis, we next focused on the effects exerted by bleomycin
F IGURE 6 Human amniotic mesenchymal stromal cells (hAMSCs) compromise the formation and expansion of bleomycin-induced lymphoid
aggregates. Bleomycin instillation induced the formation of lymphoid aggregates in lung tissue. The number and the cumulative area of
aggregates increased from days 9 to 14 postbleomycin (A). hAMSC treatment inhibited the formation of new aggregates and blocked their
expansion, indeed the number and the cumulative areas of aggregates in hAMSC-treated mice were stable from days 9 to 14 (A). In control mice
(Bleo+PBS), at day 9 postbleomycin most of the single aggregates had a size ranging from 5000 to 10 000 μm2; at day 14 their size increased and
aggregates with an intermediate (from 10 000 to 20 000 μm2) and large size (more than 20 000 μm2) developed/appeared (B). hAMSC treatment
almost abolished the expansion of single aggregates, indeed a lower number of small and intermediate aggregates and very few large aggregate
were detected (B; Bleo+hAMSC/P0 and Bleo+hAMSC/P2 groups). Control mice (Bleo+PBS) had lymphoid aggregates composed of T and B
lymphocytes in variable proportions (C). At days 9 and 14, lymphoid aggregates with an intermediate presence of B cells (10%-40% with respect
to the total lymphoid population), represented approximately 75% of the total aggregates (C, gray bars). Between days 9 and 14, the aggregates
with a higher presence of B cells (from 41% to 70%) increased (C, black bars). hAMSC treatment prevented the enrichment in B cells in lung
lymphoid aggregates (C; Bleo+hAMSC/P0 and Bleo+hAMSC/P2 groups). Data are reported as mean ± SE of n = 4 (for control and treated groups
at day 9) and n = 5 (for control and treated groups at day 14). A, *P < .05 compared to control (Bleo+PBS) group. B, *P < .05 by comparing number
of aggregates with small size (>5000 <10 000 μm2) between control (Bleo+PBS) group and treated groups (Bleo+hAMSC/P0 and Bleo+hAMSC/
P2). #P < .05 by comparing number of aggregates with intermediate size (>10 000 <20 000 μm2). C, *P < .05, **P < .01 by comparing number of
aggregates with low presence of B cells (<10 %) between control (Bleo+PBS) group and treated groups (Bleo+hAMSC/P0 and Bleo+hAMSC/P2).
#P < .05 by comparing number of aggregates with intermediate presence of B cells (>10% <40%). ‡P < .05 by comparing number of aggregates
with large presence of B cells (>41% <70%)
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instillation and hAMSC treatment on B cells. As observed with myeloid
cells and T lymphocytes, bleomycin challenge also induced recruitment
of CD19+/B220+ B lymphocytes in alveolar spaces (Figure 4A) and
upregulation of gene expression of the B-cell marker B220 in lung tissues
(Figure 4B). hAMSC treatment reduced the relative amount of alveolar B
cells at day 7 (Figure 4A), and this effect was accompanied by a decline
in the expression of B220 in lung tissue (Figure 4B). Remarkably, this
process was not transient, but it extended to the fibrotic phase (day 14)
of bleomycin-induced injury (Figure 4B).
Lastly, hAMSC treatment also reduced the number of CD138+
antibody-secreting cells present in lung tissues of bleomycin-instilled
mice (Figure 4C), suggesting an impairment of the maturation of B
cells toward antibody-secreting cells.
3.5 | hAMSCs compromise the formation and
expansion of bleomycin-induced lymphoid aggregates
Given that intrapulmonary B-cell aggregates have been found in lungs of
patients with inflammatory/fibrotic respiratory diseases,4 we evaluated B
lymphocyte distribution in lungs from bleomycin-challenged mice.
Hematoxylin and eosin analysis of lung sections evidenced the
presence of numerous lymphoid aggregates mainly located within the
peri-bronchial areas (Figure 5A,B, arrows). These aggregates were
primarily composed of CD3+ T and B220+ B lymphocytes mixed in
variable proportions (Figure 5C-F).
In bleomycin-treated animals, between days 9 and 14 postinstillation,
the number and the cumulative area of lung lymphoid aggregates mark-
edly increased, ranging from 23.0 ± 4.3 per section and 1.26 ×
105 ± 0.02 × 105 μm2 at day 9, to 54.8 ± 10.4 per section and
5.91 × 105 ± 1.69 × 105 μm2 at day 14 (Figure 6A). Interestingly, over this
time, hAMSC treatment significantly prevented the formation of new
aggregates and blocked the increment of cumulative area (Figure 6A).
Next, we examined the ability of hAMSCs to influence the expan-
sion of single lymphoid aggregates. At day 9, most of the aggregates
ranged from 5000 to 10 000 μm2 (Figure 6B, upper panel), whereas at
day 14 more than 25% of the aggregates had an intermediate size (from
10 000 to 20 000 μm2) and some bigger aggregates appeared (higher
than 20 000 μm2; Figure 6B, lower panel). hAMSC treatment almost
abolished the expansion of single lymphoid aggregates at day 14, as indi-
cated by the presence of only few small and intermediate aggregates
and very few large aggregates (Figure 6B, lower panel).
Finally, we explored whether hAMSCs affected the cellular com-
position of the aggregates.
At days 9 and 14, lymphoid aggregates with an intermediate pres-
ence of B cells (10%-40% with respect to the total cell lymphoid pop-
ulation), represented approximately 75% of the total aggregates
(Figure 6C, gray bars). Between days 9 and 14, the aggregates with a
F IGURE 7 Human amniotic mesenchymal stromal cell (hAMSC) treatment reduces the expression of chemokines/cytokines involved in
pulmonary recruitment and retention of B lymphocytes. Compared to saline-instilled mice, bleomycin challenge upregulated the gene expression
of lymphotoxin (A, Bleo+PBS group), CCL21 (B), CXCL12 (C), and CXCL13 (D), which promote the recruitment and retention of lymphocytes into
lung tissue. Expression of lymphotoxin, CCL21, and CXCL12 were early and transiently increased, whereas CXCL13 expression (the most
effective chemoattractant for B cells) was high at all time points. hAMSC treatment accelerated the normalization of expression of lymphotoxin,
CCL21 and CXCL12, and reduced CXCL13 expression at all time points. In addition, bleomycin challenge increased BAFF gene expression (E, Bleo
+PBS group), a cytokine with a crucial role for B-cell survival. hAMSC treatment reduced BAFF expression at days 4 and 7 (E). Data are expressed
as log2 of the fold change expression from the saline-instilled group, and are reported as mean ± SE of n = 3 (day 2), n = 4 (day 4), and n = 5-7
(days 7 and 9). *P < .05, **P < .01, ***P < .01 compared to control (Bleo+PBS) group
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higher presence of B cells (from 41% to 70%) increased from 18.5%
± 2.3% (at day 9) to 26.6% ± 5.2% (Figure 6C, black bars). Interest-
ingly, at day 14, hAMSC treatment reduced the number of B cells into
the lymphoid aggregates (Figure 6C). Overall, these data indicate that
hAMSCs blocked the formation, expansion, and B-cell enrichment of
lung lymphoid aggregates.
To provide insight onto how hAMSCs affected B-cell lymphoid
aggregates, we investigated B-cell recruitment, survival, and prolifera-
tion after treatment.
To investigate whether hAMSCs can affect the recruitment of lym-
phocytes in lung tissues, we performed gene expression analysis of the
main chemokines involved in recruitment and retention of lymphocytes
(lymphotoxin, CCL21, CXCL12, and CXCL13), and known to contribute to
the generation of lymphoid aggregates in various organs.34,35 As indicated
in Figure 7, bleomycin treatment transiently increased the expression of
lymphotoxin, CCL21, and CXCL12 (Figure 7A-C), while CXCL13, previ-
ously suggested to be a potent chemokine for B cells,36 remained highly
expressed at all time points (Figure 7D). By day 4, hAMSC treatment
reduced lung expression of all the chemokines examined (Figure 7A-D).
To inquire into the ability of hAMSCs to interfere with the pro-
duction and/or secretion of factors crucial for B-cell survival, we ana-
lyzed the expression of A proliferation-inducing ligand (April) and B-
cell-activating factor (BAFF). Neither bleomycin nor hAMSC treatment
altered the expression of April in lung tissue (data not shown). On the
other hand, bleomycin upregulated BAFF expression at all time points
and hAMSCs reduced its expression at day 4 (Figure 7E).
We next sought to ascertain the effect of hAMSCs on B-cell pro-
liferation. Analysis of Ki67 positive cells revealed that only a small
number of B cells present in lymphoid aggregates proliferate (data not
shown), thus suggesting that most of B cells may be recruited from
extrapulmonary compartments.
4 | DISCUSSION
In this study, we investigated if amniotic mesenchymal stromal cells
(hAMSCs) isolated from human term placenta interfere with the
inflammatory response in a mouse model of pulmonary fibrosis. For
the first time, we demonstrate the ability of hAMSCs to impair lung B-
cell response and we propose this as a possible mechanism crucial to
reduce the progression of fibrotic lesions.
In agreement with ours and others' previous studies performed in
bleomycin-induced and in other models of fibrosis,7-10,18,24 our data
confirm the ability of hAMSCs to reduce fibrosis development and
demonstrate their efficiency in lowering the inflammatory milieu cre-
ated by bleomycin instillation. hAMSCs, by reducing costimulatory
protein expressions in dendritic cells and in monocyte-derived macro-
phages, possibly reduce their ability to induce antigen-specific T-cell
immune responses. Moreover, hAMSCs promote the generation of
immune cells (Treg) and cytokines (IL-10) with immune regulatory
functions in diseased lungs.
Importantly, our data show that hAMSCs affect the kinetics of
B-cell recruitment and B-cell homing throughout the entire fibrotic
process, from the early inflammatory phase (days 2-7) to the late
fibrotic phase (days 7-14) of bleomycin-induced lung injury. We found
indeed that hAMSC treatment constantly reduced the relative amount
of B cells in alveolar spaces and lung expression of B220, a murine
B-cell marker, suggesting this as a possible mechanism of hAMSCs to
contrast lung fibrosis. Moreover, our data underline the potential
involvement of B cells in the pathogenesis of bleomycin-induced
fibrotic lesions already proposed by some authors. Komura and
collaborators37 reported that genetically modified mice lacking B-cell
surface molecule CD19 displayed a reduced susceptibility to
bleomycin-induced fibrosis. Francois and collaborators38 observed
that genetic ablation of BAFF attenuates pulmonary fibrosis and
O'Donoghue and collaborators39 detected reduced fibrosis in mutant
mice deficient in mature B lymphocytes, challenged with bleomycin.
In addition, the presence of lymphoid aggregates has been described
in the lungs of mice challenged with bleomycin,40 of mice genetically
modified (CCR7−/− mice) showing an impaired homing of Treg cells,41
and of mice with rheumatoid arthritis-related interstitial lung disease.42
Here, we also detected intrapulmonary aggregates composed of T
and B lymphocytes in bleomycin-instilled animals and we demon-
strated that hAMSC treatment inhibited the formation and expansion
of these aggregates.
Although the role of lung lymphoid aggregates is controversial, a
growing body of clinical evidence strongly points at the contribution
of intrapulmonary T/B-cell aggregates in the initiation and/or progres-
sion of a range of fibrotic diseases such as IPF1,2,43,44 and nonspecific
interstitial pneumonia.45 In the lungs of IPF patients, B cells form focal
aggregates together with T lymphocytes and their number has been
correlated with the development and severity of lung fibrotic
lesions.2,45 In addition, as observed herein, B lymphocytes present in
these aggregates do not proliferate,1,2,40,43 suggesting that recruit-
ment from systemic circulation likely represents the main mechanism
leading to lymphocyte accumulation in lung parenchyma.
Importantly, our data suggest that hAMSC treatment can reduce
B-cell recruitment and homing by inhibiting the lung expression of
homeostatic lymphoid chemokines, essentially CXCL13, a crucial chemo-
attractant for B cells,36 and by reducing BAFF, that holds a major role in
B-cell survival and maturation and can thereby promote lymphoid aggre-
gate formation.46 It is of note that in IPF patients, increased plasma con-
centrations of BAFF (or BLyS) correlated with clinical severity and
negative outcomes of these patients43 and longitudinal increment of
plasma levels of CXCL13 and high lung expression of CXCL13 have been
associated with severe clinical manifestations and disease progression.44
Besides B and T cells and their mediators, other immune cells may
participate in supporting the formation and expansion of intrapulmonary
lymphoid aggregates. Dendritic cells, for example, have been suggested
to be crucial in maintaining lymphoid aggregates in lungs from influenza
virus-infected mice, both by providing lymphotoxin and CXCL13 neces-
sary to B-cell homing and retention and by promoting T-cell activation.47
Moreover, macrophages represent a potent inducible source of CXCL13
in chronic inflammatory diseases associated with formation of T- and
B-cell aggregates, such as rheumatoid arthritis and ulcerative colitis,
where they possibly play a role in the genesis of the lymphoid tissue.48
hAMSCs MODULATE B-CELL RESPONSE IN LUNGS OF MICE 11
Considering that hAMSC treatment impaired the antigen presenting
potential of dendritic cells and monocyte-derived macrophages, we
hypothesize that this also may contribute to the ability of hAMSCs in
controlling lymphoid aggregate formation/expansion and fibrosis pro-
gression in bleomycin-injured lungs.
Altogether, we propose that in bleomycin-challenged mice,
hAMSCs create an anti-inflammatory microenvironment partially
mediated by their ability to control recruitment, retention, and matu-
ration of B cells in diseased lungs. Within the lymphoid aggregates, B
cells can continuously act as antigen presenting cells for the adjacent
T lymphocytes and can cause cytotoxicity by producing autoanti-
bodies. hAMSCs can resolve this loop and hence break the self-
maintaining inflammatory condition promoted by B cells.43,44,49
Finally, in an attempt to support the clinical application of
hAMSC-based therapy, this study tried to address the important ques-
tion on the impact of in vitro expansion on hAMSC therapeutic
effects. In this study, indeed two different cell preparations were
used: freshly isolated hAMSCs (hAMSC/P0) and hAMSCs expanded
in vitro to passage 2 (hAMSC/P2). In bleomycin-induced pulmonary
injury model, both treatments displayed similar effects on the immune
populations investigated in this study, suggesting that at least a short-
term expansion in vitro does not alter cell activity.
5 | CONCLUSION
Our work provides key insights into the therapeutic potential of hAMSCs
from an immunological perspective, providing further evidence for a
potential clinical translation of hAMSCs in inflammation-related
fibrotic diseases. In support of this, short-term in vitro expansion
(passage 2) did not alter the activity of hAMSCs in comparison to
freshly isolated cells (passage 0), thus further encouraging the
translation of this therapeutic product into the clinic. However,
given the need of high numbers of cells also for potential repeated
treatments, studies elucidating the influence of in vitro long-term
expansion on cellular functions are needed.
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